Loading clinical trials...
Loading clinical trials...
A Phase I Feasibility Trial IP Cisplatin and IV Paclitaxel on Day 1 Followed by IP Paclitaxel on Day 8 Every 21 Days as Front-Line Treatment of Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma
Conditions
Interventions
Paclitaxel
Cisplatin
Locations
7
United States
University of Chicago Comprehensive Cancer Center
Chicago, Illinois, United States
University of Iowa Hospitals and Clinics
Iowa City, Iowa, United States
Cooper Hospital University Medical Center
Camden, New Jersey, United States
Riverside Methodist Hospital
Columbus, Ohio, United States
Tulsa Cancer Institute
Tulsa, Oklahoma, United States
Women and Infants Hospital
Providence, Rhode Island, United States
Start Date
February 1, 2009
Primary Completion Date
July 1, 2011
Last Updated
December 31, 2014
NCT05969860
NCT06710548
NCT06290193
NCT06399757
NCT06855706
NCT05271318
Lead Sponsor
Gynecologic Oncology Group
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions